Amicoat

Executive Summary

Amicoat is a Norwegian biotechnology company pioneering a patented antimicrobial peptide (AMP) coating technology, voxvoganan, designed to reduce healthcare-associated infections (HAIs) on medical devices. Founded in 2018 and based in Oslo, the company leverages natural defense mechanisms to create a sustainable, next-generation antimicrobial solution. By coating devices such as catheters and implants, Amicoat aims to address a critical unmet need in infection prevention, potentially reducing reliance on traditional antibiotics and combating antimicrobial resistance. As a private, early-stage company, Amicoat is positioned to disrupt the medical device coating market, which is valued at billions globally. However, its success depends on clinical validation, regulatory approvals, and strategic partnerships with device manufacturers. The company's technology has the potential to significantly improve patient outcomes and lower healthcare costs, but it faces competition from existing antimicrobial coatings and regulatory hurdles.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major medical device manufacturer for co-development and commercialization40% success
• Q3 2026Publication of preclinical in vivo efficacy data demonstrating reduction in biofilm formation on coated catheters50% success
• Q2 2027Series A funding round to support clinical trials and scale-up manufacturing35% success